Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Lisata Therapeutics, Inc.
< Previous
1
2
Next >
Lisata Therapeutics to Present at the Investival Showcase USA
March 06, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
March 05, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
February 20, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
February 05, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
January 23, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
January 22, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
January 15, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
December 10, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
December 03, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
November 19, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
November 06, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
November 06, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
October 31, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
October 28, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
October 03, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
September 17, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
September 09, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
September 05, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
August 05, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
July 16, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
July 10, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
June 13, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
May 28, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
May 20, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events
May 08, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
May 02, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Tickers
LSTA
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.